[Risk and prognosis of corpus carcinomas after tamoxifen treatment of breast carcinoma]

Strahlenther Onkol. 2001 Jul;177(7):371.
[Article in German]

Abstract

Background: Dysphagia after radiotherapy of thoracic tumors may be caused by recurrences or by radiation damage to the esophagus.

Case report: A 75-year-old patient presented with a complete obstruction of the esophagus 5 months after CHARTWEL radiotherapy for a non-small cell lung cancer. During the last week of radiotherapy mild dysphagia (Grade 1 EORTC/RTOG, Grade 2 MRC-CHART-Score) occurred that persisted over the following months. X-ray and endoscopic investigations revealed an easily removable food bolus without evidence of esophageal stricture or ulceration.

Conclusion: The case report describes a mild but prolonged early radiation reaction of the esophagus. In comparison with conventional fractionation the incidence of dysphagia is higher after accelerated fractionation schedules. The pathophysiologic mechanisms underlying persistent dysphagia are currently unknown. Beside of recurrences, radiation effects to the esophagus should be considered if dysphagia after irradiation of thoracic tumors occurs, because, as in this case, therapy may rapidly improve the symptoms.

Publication types

  • English Abstract

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Case-Control Studies
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Neoplasm Staging
  • Neoplasms, Second Primary / chemically induced*
  • Neoplasms, Second Primary / genetics
  • Neoplasms, Second Primary / pathology
  • Prognosis
  • Risk
  • Tamoxifen / adverse effects*
  • Tamoxifen / therapeutic use
  • Tumor Suppressor Protein p53 / genetics
  • Uterine Neoplasms / chemically induced*
  • Uterine Neoplasms / genetics
  • Uterine Neoplasms / pathology
  • Uterus / drug effects
  • Uterus / pathology

Substances

  • Tumor Suppressor Protein p53
  • Tamoxifen